Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 5Terminated 2Recruiting 2Completed 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 19Carcinoid Tumor 7Pheochromocytoma 6Thyroid Carcinoma, Anaplastic 5Pituitary Neoplasms 5Paraganglioma 5Insulinoma 5Somatostatinoma 4Vipoma 3Serotonin Syndrome 3Lung Neoplasms 3Glucagonoma 3Gastro-enteropancreatic neuroendocrine tumor 3Gastrinoma 3Carcinoma, Neuroendocrine 3Carcinoma, Merkel Cell 3Carcinoma, Medullary 3Carcinoma, Islet Cell 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms, Unknown Primary 2Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Head and Neck Neoplasms 2Growth Hormone-Secreting Pituitary Adenoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2

Interventions

Temozolomide 1Microarray Analysis 1DNA Methylation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Prolactinoma × Endocrine × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡